The purpose was to investigate the effect of neutralization of rat interleukin-6 (IL-6) bioactivity on the activity levels of Na + -K + /Mg ++ adenosine-5 0 -triphosphatase and superoxide dismutase, and the degree of infarct size in ischemic brain produced by experimental middle cerebral artery occlusion in the rat. Seventy adult male Wistar rats weighing 280 to 310 g were used in this study. The animals were randomly allocated to groups: group I (n = 10) consisted of normal controls, group II (sham-operated, n = 20) underwent surgical exposure of the middle cerebral artery but no cauterization, and the remaining 40 rats were subjected to middle cerebral artery occlusion. Immediately after occlusion, each of these 40 rats was randomly assigned to either the occlusion-only group (group III, n = 20) or the occlusion plus IL-6 antibody treatment group (group IV, n = 20). All evaluations were performed in blinded fashion. Our data provide evidence that neutralization of IL-6 bioactivity correlates with less secondary damage in long-term treatment after focal cerebral ischemia in the rat.
C erebral artery occlusion results in ischemic brain injury owing to both the cessation of blood flow and the initiation of secondary injury mechanisms. After ischemia and trauma, superoxide radicals accumulate in the intracellular and extracellular spaces. Superoxide radicals generally seem to exacerbate ischemic injury. [1] [2] [3] Interleukin-6 (IL-6), which is one of the main inflammation-associated cytokines, is produced by a variety of cells in the central nervous system (CNS). 4 Investigations have demonstrated elevated cerebrospinal fluid (CSF) levels of this mediator in noninfectious CNS inflammatory diseases. [5] [6] [7] [8] [9] Vila et al 10 found that in patients with acute ischemic stroke, those with higher levels of IL-6 had more severe neurologic deficits upon admission and greater infarct size. IL-6 has no direct influence on acute ischemic injury; however, subjects who overexpress IL-6 are known to exhibit early neurodegenerative changes. [11] [12] [13] On the basis of what is currently known, it is conceivable that neutralization of IL-6 bioactivity can decrease the level of superoxide radicals, and thus reduce secondary damage. Superoxide dismutase (SOD) is a specific free-radical scavenger.
14 Na + -K + -activated adenosine-5 0 -triphosphatase (ATPase) is responsible for maintaining the membrane potential. 15, 16 This enzyme is highly susceptible to free-radical reactions and lipid peroxidation 17 ; thus, its activity is reduced in damaged tissue. 18, 19 In this study, the purpose was to investigate the effect of neutralization of rat IL-6 bioactivity on the activity levels of Na + -K + /Mg ++ ATPase and SOD and the degree of infarct size in ischemic brain produced by experimental middle cerebral artery occlusion (MCAO) in the rat.
MATERIALS AND METHODS
Seventy adult male Wistar rats weighing 280 to 310 g were used in this study. The animals were randomly allocated to groups: group I (n = 10) consisted of normal controls; group II (sham-operated, n = 20) underwent surgical exposure of the middle cerebral artery (MCA) but no cauterization; and the remaining 40 rats were subjected to MCAO. Immediately after occlusion, each of these 40 rats was randomly assigned to either the occlusion-only group (group III, n = 20) or the occlusion plus IL-6 antibody treatment group (group IV, n = 20). All evaluations were performed in blinded fashion.
All animals were anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (10 mg/kg). MCAO was performed using a technique that was initially introduced by Tamura et al 20 but modified by Menzies et al. 21 All surgical procedures were carried out with the aid of an operating microscope. The right MCA trunk was exposed via a right subtemporal craniectomy using a saline-cooled dental drill. The dura mater was then carefully incised and reflected. Three to 6 mm of the main MCA in the region between the origin of the lateral striate artery and the inferior cerebral vein was cauterized using bipolar forceps under the surgical microscope. The wound was closed in layers.
Group I (the controls) was used to determine normal Na
++ ATPase and SOD activities in the absence of surgery or medication. Group II (shamoperated) underwent craniectomy and received an intraperitoneal injection of saline equal in volume to the injection of antirat IL-6 given to the antibody-treated group. The aim here was to determine the impact of craniectomy alone on the biochemical factors measured. Group III (occlusion only) received an intraperitoneal saline injection identical to that described above immediately after MCAO. Group IV (antirat IL-6 antibodytreated) received 1 intraperitoneal injection of antirat IL-6 antibody (5 mg) (Ig class: recombinant rat IL-6-specific goat IgG, R&D Systems, Biotech Division, Minneapolis, catalog number: AF506) immediately after occlusion, a second dose (5 mg) 24 hours later, and a third dose (5 mg) at 48 hours postocclusion.
Half of the rats from each of groups II, III, and IV were killed at 24 hours, and the other half at 72 hours after craniectomy alone (group II) or occlusion (groups III and IV). This created 2 subgroups per group, with groups A-II, A-III, and A-IV killed at 24 hours and groups B-II, B-III, and B-IV at 72 hours. In group IV, the 10 rats that were killed at 24 hours postocclusion received 1 dose and the other 10 that were killed at 72 hours, received 3 doses. Each rat was killed by decapitation after it was anesthetized. In groups A-III, A-IV, B-III, and B-IV, after the brains were quickly removed, they were prepared for evaluation of the infarct area. We used 2-dimensional data to estimate surface area of the lesion, as defined by Menzies et al. 21 Using an operating microscope, the margins between the pale discoloration of the ischemic and the surrounding healthy tissues were delineated. Using a transparent grid with 1-mm 2 pixel size made from chart recording paper, the surface area of each lesion was measured by adding the number of square pixels overlying the infracted area. Then, in all groups, tissues for assays of Na + -K + /Mg ++ ATPase and SOD were taken from the ischemic core, and these included areas of second grade and third grade ischemia, as defined by Menzies et al. 21 The sample from the ischemic core was divided coronally into 2 consecutive blocks that were assigned numbers, counting from anterior to posterior. These blocks were stored in a À 801C freezer for assays of the enzymes. The first block was used for the assay of Na + -K + / Mg ++ ATPase and the second for the assay of SOD.
Determination of Na + -K + /Mg ++ ATPase Activity
Ten percent homogenates of the tissue were prepared in 0.3-M sucrose containing 1-mM magnesium by homogenizing for 90 seconds using a Teflon pestle clearance of 0.25 to 0.38 mm at 1000 rpm. ATPase activity was determined in the resulting supernatants by measuring the rate of liberation of inorganic phosphate from disodium ATP. 22 Incubation media were prepared as described previously. 23 The ATPase activity levels were determined as follows: for each sample, 6-mM MgCl 2 , 5-mM KCl, 100-mM NaCl, 0.1-mM ethylene diamine tetra acetic acid, and 135-mM tris-HCl buffer of pH 7.4 were mixed together in a 1-ml tube. After preincubation for 5 minutes at 371C, Na 2 ATP was added to each tube to reach a final concentration of 3 mM. The blank sample that contained no enzyme, the standard, and the unknowns were incubated at 371C for 30 minutes. We then stopped the reaction by placing the samples on ice. Inorganic phosphate was determined in 1-ml aliquots of the incubated mixtures by adding lubrol-molybdate solution, vortexing, and allowing the mixtures to stand at ambient temperature for 10 minutes. Extinction at 240 nm was measured. All assays were carried out in triplicate, and were run with enzyme and reaction blanks. Samples were compared for phosphate content with standards of KH 2 PO 4 . Specific activity was calculated as nanomoles of inorganic phosphate/h/mg of protein.
All reagents were of Analar grade unless otherwise stated. Na 2 ATP was obtained from Boehringer-Mannheim Ltd (Mannheim, Germany), and lubrol type Px was obtained from Sigma Chemical Co Ltd (St Louis, MO). The lubrol-molybdate solution was prepared according to the method of Reading and Isbir. 22, 23 The protein content was determined according to the method described by Lowry et al, 24 and bovine serum albumin was used as a standard.
Determination of SOD Activity
We isolated SOD from the brain tissue in a preparation as described by Yarborough. 25 The pyrogallol method was used to measure SOD activity, with a slight modification detailed by Roth and Gilbert. 26 Specific activities were calculated as units per gram of protein.
The Mann-Whitney U test was used for all statistical analyses.
RESULTS

Na
+ -K + /Mg ++ ATPase Activity Figure 1 shows the effect of ischemic injury with and without antirat IL-6 antibody treatment on Na + -K + / Mg ++ ATPase activity in brain homogenates measured at 24 and 72 hours after occlusion. The decreased activity noted in the sham-operated groups did not differ statistically from the findings in the control group (P>0.05). Ischemic injury alone resulted in significantly lower Na + -K + /Mg ++ ATPase activity in the ischemic core than that seen in both controls and sham-operated rats at both time points postocclusion (P<0.05). The increased activity noted in group A-IV did not differ statistically from the values determined in group A-III (P>0.05). In group B-IV, antirat IL-6 antibody treatment significantly attenuated the decrease in Figure 2 shows the effect of ischemic injury with and without antirat IL-6 antibody treatment on SOD activity in brain homogenates after 24 and 72 hours of occlusion. SOD activity was higher in the sham-operated animals than in the control group, but the difference was not statistically significant (P>0.05). The activity was significantly higher in the occlusion-only animals than in the sham-operated and control groups (P<0.05). The decreased activity noted in group A-IV did not differ statistically from the values determined in group A-III (P>0.05). Antirat IL-6 antibody treatment significantly decreased SOD activity at 72 hours postocclusion, compared with the findings in the occlusion-only group (P<0.05). Figure 3 shows the effect of ischemic injury with and without antirat IL-6 antibody treatment on the size of infarction at 24 and 72 hours postocclusion. The reduced infarct size noted in group A-IV did not differ statistically from the values determined in group A-III (P>0.05). In group B-IV, antirat IL-6 antibody treatment significantly reduced the size of infarction that was observed in group B-III (P<0.05).
SOD Activity
Evaluation of the Infarction
DISCUSSION
As brain tissue contains large amounts of lipids cerebral ischemia plus the free-radical reactions and lipid peroxidation that accompany it, may lead to considerable cell membrane injury. [27] [28] [29] [30] Treatments that decrease the level of these radicals can effectively reduce ischemic brain injury. [1] [2] [3] It is known that after focal cerebral ischemia, CSF level of IL-6 elevates in the CNS; in addition, elevated CSF and plasma levels of this mediator are correlated with less favorable prognosis and larger infarct size. [31] [32] [33] [34] Block et al 35 demonstrated that 1 day after MCAO in rats, there were several IL-6-positive microglia and neurons in the ischemic penumbra, and this expression of IL-6 increased on day 3 and remained elevated up to day 14. Gijbels et al 36 reported that systemically administered IL-6 antibody penetrates the CSF in animals with noninfectious CNS inflammatory disease. Applying antiserum that has been raised against a particular hormone or chemical compound can neutralize the function of that compound in vivo. 37 These data were our basis for using anti-IL-6 antibody and testing the levels of Na + -K + /Mg ++ ATPase and SOD, and the degree of infarct size as indicators of the effect of the antibody in ischemic tissues at 24 and 72 hours postocclusion.
It was necessary to take account of a number of factors in determining the dosage and administration of the antibody. Experimental studies have demonstrated that peak serum and CSF levels (approximately 1200 pg/mL) of IL-6 after MCAO in mice occur at approximately 6 hours, with the 24-hour value being close to 25% of the maximum. 32, 38 The exact concentration of antibody required to neutralize rat IL-6 activity is dependent on the IL-6 concentration. However, the exact IL-6 concentration in the rat CNS after occlusion is not known. To provide a guideline, R&D Systems has determined the neutralization dose (ND 50 ) for this antibody under a specific set of conditions. The ND 50 for this antibody is defined as the concentration of antibody required to yield one-half maximal inhibition of IL-6 activity on a responsive cell line. The ND 50 of antirat IL-6 antibody was determined to be 0.03 to 0.09 mg/mL in the presence of 0.6 ng/mL of rrIL-6 (R&D Systems). Accordingly, the ND 50 of the antirat IL-6 antibody used in this study was determined to be approximately 5 mg on the basis of previous reports, 32,38 a rat's body weight, blood volume, and CSF volume. As detailed, we used a dose of 5 mg at each injection in the treated rats.
As the inflammation-associated IL-6 causes freeradical production during secondary injury, it is logical that, over time, SOD would rise in parallel with the increasing levels of free radicals. In our study, the changes in SOD and Na + -K + /Mg ++ ATPase activities in the antibody-treated rats indicate that neutralizing IL-6 bioactivity partly decreases the level of free-radical production in the ischemic brain. Compared with the control and the sham-operated subgroups, the untreated groups exhibited significantly increased SOD and decreased Na + -K + /Mg ++ ATPase activities at both time points after occlusion. A single 5-mg dose of antirat IL-6 antibody did not significantly affect the levels of SOD and Na + -K + /Mg ++ ATPase when testing was carried out 24 hours after occlusion. On the other hand, administering 3 doses of the antibody resulted in a significant decrease in SOD level and a significant increase in Na + -K + / Mg ++ ATPase activity compared with those seen in the occlusion-only subgroup at 72 hours after occlusion. This higher ATPase activity was associated with decreased SOD level and fits with interpretation for SOD given above. A single dose of the antibody had no effect on ischemic injury-induced infarct size when testing was carried out 24 hours after occlusion. However, administering 3 doses of the antibody reduced the size of infarction compared with the findings in the occlusiononly group when testing was carried out 72 hours postocclusion. These structural changes also correlated well with the biochemical findings.
It seems that multiple doses of anti-rat IL-6 antibody and a longer duration of the treatment are required to neutralize IL-6 bioactivity, and thus decrease free-radical production. This is in agreement with previous findings that various inhibitors act in a dosedependent manner to reduce neurotoxicity in in vivo settings. [39] [40] Another possible explanation for our findings may be that neutralization of IL-6 (an inflammatory mediator) decreases the influx of inflammatory cells, such as neutrophils, into the CNS. 5 This may also result in attenuation of in vivo lipid peroxidation during the process of secondary injury. The expected end result is less secondary neurologic damage.
Our data provide evidence that neutralization of IL-6 bioactivity correlates with less degree of secondary damage in long-term treatment after focal cerebral ischemia in the rat. 
